Changes to Revenio ‘s organizational structure and Leadership Team
Revenio Group Company is renewing its company structure in order in order to support the company’s growth. Over the particular past two years, Revenio has gone through the significant evolution from an equipment supplier to a global leader of comprehensive eye diagnostics solutions. The objective of the change within the organizational structure is to support the solution business and the increasingly stronger customer experience by centralizing the Products, Brand plus Marketing as well because Sales into their own units. The Research and Product Development operations, which were previously decentralized, will also be brought together in a single unit to serve the particular Group’s business operations centrally. In addition, a Strategy and Business Development unit will be established to support the company’s strategic objectives, which will be responsible for clinical applications, tactical partnerships plus thought leadership. The new company structure will certainly enter into force on Feb 1, 2023 .
“Our business is based on sustainable and profitable development. With the new organizational model, we will assistance our growth and clarify the management and transparency of our proper priorities. We used to operate in the equipment business but, as a result of the acquisitions, our business furthermore covers software expertise. This requires a change of operating model. From the point associated with view of customer encounter, it will be important that we can offer our services and products by the same teams, using the exact same distribution channels in all in our markets, ” emphasizes CEO Jouni Toijala .
Changes in the responsibilities of the particular Leadership Group
The brand new organizational framework will bring changes to the obligations of the Leadership Team and introduce one new member to the particular Leadership Group. Tomi Karvo , who was previously responsible for sales plus marketing, takes full responsibility for the Items, Brand and Marketing unit’s operations. John Floyd has been appointed Vice President, Sales, and a member associated with the Management Team. He has long served since CEO of Revenio ‘s subsidiary Icare USA Inc in the United States , where he was also responsible for sales. Kate Taylor , formerly responsible with regard to the Eye Care Solutions company, has been hired Vice Chief executive of the new Strategy plus Business Advancement unit.
Giuliano Barbaro , who has successfully led the Research and Application unit, offers announced that he will take up brand new responsibilities outside the company and will continue in his position until the end associated with June, and he will ensure a controlled transfer of his tasks during the Spring. The search for the particular new Vice President for that Research and Product Growth unit may be launched immediately.
“I warmly thank Giuliano regarding his outstanding and groundbreaking work intended for Revenio plus wish him every success within the development of therapies for treatment of cancer diseases. At the same time, I warmly welcome John Floyd as a member from the Leadership Team. I also wish Kate Taylor , who will continue in a new role in the particular Leadership Team, every achievement. I am very pleased that we have found talented managers through internal transfers for these new important roles, ” says Jouni Toijala .
Composition and responsibilities of the Revenio Team Leadership Group as of February 1, 2023 :
- Jouni Toijala , CEO
- Giuliano Barbaro , Vice President, Research and Product Development until June 30, 2023
- Steve Floyd , Vice Leader, Sales – Member associated with the Management Team starting from Feb 1, 2023
- Heli Huopaniemi, Vice President, Quality
- Ari Isomäki, Vice President, Operations
- Tomi Karvo , Vice President, Products, Brand plus Marketing
- Robin Pulkkinen , CFO
- Kate Taylor , Vice Chief executive, Strategy and Business Development
- Hanna Vuornos, Vice Leader, People plus Culture
The change in the particular organizational design supports the implementation of the strategy. Revenio can update its strategy with the support of the new organization during the particular Spring.
The particular CV associated with John Floyd , that will start as a new member of Revenio’s Leadership Team on February 1, 2023 , is usually attached in order to this release. The CVs from the current members of Revenio ‘s Leadership Team can be found on Revenio is website at https://www.reveniogroup.fi/en/investors/corporate_governance/leadership_team
For further information, please contact Jouni Toijala , CEO, tel. +358 50 484 0085
jouni. [email protected] fi
Distribution
Nasdaq Helsinki
FIN-FSA
Key media
www.revenio.fi/en
Revenio Group in brief
Revenio is a leading company in the global market to get ophthalmological devices and software program solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters because well since clinical software under the iCare brand. iCare is a trusted partner within ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools pertaining to the diagnosis of glaucoma, diabetic retinopathy, plus macular degeneration (AMD). iCare Solutions provide digital medical tools that will drive greater efficiency and enhance quality in vision care.
In 2021, the Group’s net sales totaled EUR 78. 8 million , with an operating profit of EUR 22. 1 million . Revenio Group Corporation is definitely listed upon Nasdaq Helsinki with the particular trading code REG1V.
